Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleBehavioral Pharmacology

Pharmacological Characterization of a Dopamine Transporter Ligand That Functions as a Cocaine Antagonist

Rajeev I. Desai, David K. Grandy, Carl R. Lupica and Jonathan L. Katz
Journal of Pharmacology and Experimental Therapeutics January 2014, 348 (1) 106-115; DOI: https://doi.org/10.1124/jpet.113.208538
Rajeev I. Desai
Psychobiology Section (R.I.D., J.L.K.) and Electrophysiology Research Section (C.R.L.), National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland; and Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon (D.K.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David K. Grandy
Psychobiology Section (R.I.D., J.L.K.) and Electrophysiology Research Section (C.R.L.), National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland; and Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon (D.K.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carl R. Lupica
Psychobiology Section (R.I.D., J.L.K.) and Electrophysiology Research Section (C.R.L.), National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland; and Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon (D.K.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan L. Katz
Psychobiology Section (R.I.D., J.L.K.) and Electrophysiology Research Section (C.R.L.), National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland; and Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon (D.K.G.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Article Information

vol. 348 no. 1 106-115
DOI 
https://doi.org/10.1124/jpet.113.208538
PubMed 
24194528

Published By 
American Society for Pharmacology and Experimental Therapeutics
Print ISSN 
0022-3565
Online ISSN 
1521-0103
History 
  • Received August 1, 2013
  • Accepted November 4, 2013
  • Published online December 14, 2013.

Article Versions

  • Earlier version (November 5, 2013 - 10:46).
  • You are viewing the most recent version of this article.
Copyright & Usage 
U.S. Government work not protected by U.S. copyright

Author Information

  1. Rajeev I. Desai1,
  2. David K. Grandy,
  3. Carl R. Lupica, and
  4. Jonathan L. Katz
  1. Psychobiology Section (R.I.D., J.L.K.) and Electrophysiology Research Section (C.R.L.), National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland; and Department of Physiology and Pharmacology, Oregon Health and Science University, Portland, Oregon (D.K.G.)
  1. Address correspondence to:
    Dr. Jonathan L. Katz, Psychobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, 251 Bayview Blvd, Suite 200, Baltimore, MD 21224. E-mail: jkatz{at}intra.nida.nih.gov
View Full Text

Statistics from Altmetric.com

Article usage

Article usage: November 2013 to January 2023

AbstractFullPdf
Nov 20131990110
Dec 20134701668
Jan 20142481744
Feb 20141431118
Mar 20141381114
Apr 2014105911
May 2014991314
Jun 201493215
Jul 201456610
Aug 20143526
Sep 20143864
Oct 20143488
Nov 20141345
Dec 20142387
Jan 2015431314
Feb 20151571
Mar 20152579
Apr 2015121010
May 201512114
Jun 201528715
Jul 20151249
Aug 20151372
Sep 2015271611
Oct 20151054
Nov 20151467
Dec 20152046
Jan 201626510
Feb 2016902
Mar 201614211
Apr 20162348
May 201617412
Jun 20161448
Jul 20161929
Aug 201623612
Sep 2016755
Oct 20163178
Nov 20163169
Dec 2016183
Jan 20170156
Feb 20170152
Mar 20170144
Apr 201722412
May 20171119
Jun 201721310
Jul 20170510
Aug 2017089
Sep 201711011
Oct 201711220
Nov 201721212
Dec 20171125
Jan 20180110
Feb 20182812
Mar 20180610
Apr 201811211
May 20181169
Jun 2018098
Jul 20182146
Aug 2018076
Sep 2018068
Oct 20181614
Nov 20180615
Dec 2018119
Jan 20191013
Feb 20197012
Mar 201911010
Apr 2019808
May 2019304
Jun 2019720
Jul 2019715
Aug 20191003
Sep 20191600
Oct 20192510
Nov 20191763
Dec 2019632
Jan 20201420
Feb 2020711
Mar 2020701
Apr 2020432
May 2020711
Jun 2020300
Jul 20201111
Aug 2020403
Sep 2020723
Oct 20202400
Nov 2020502
Dec 20201311
Jan 2021501
Feb 2021822
Mar 20212511
Apr 2021510
May 2021821
Jun 2021710
Jul 2021312
Aug 2021711
Sep 2021422
Oct 2021710
Nov 20211923
Dec 20211402
Jan 2022917
Feb 2022611
Mar 2022711
Apr 20221537
May 2022421
Jun 2022842
Jul 2022821
Aug 20221625
Sep 20222158
Oct 2022812
Nov 20221521
Dec 20221212
Jan 2023821

PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 348 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 348, Issue 1
1 Jan 2014
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Pharmacological Characterization of a Dopamine Transporter Ligand That Functions as a Cocaine Antagonist
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleBehavioral Pharmacology

Cocaine-Antagonist Effects of BZT Analogs

Rajeev I. Desai, David K. Grandy, Carl R. Lupica and Jonathan L. Katz
Journal of Pharmacology and Experimental Therapeutics January 1, 2014, 348 (1) 106-115; DOI: https://doi.org/10.1124/jpet.113.208538

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleBehavioral Pharmacology

Cocaine-Antagonist Effects of BZT Analogs

Rajeev I. Desai, David K. Grandy, Carl R. Lupica and Jonathan L. Katz
Journal of Pharmacology and Experimental Therapeutics January 1, 2014, 348 (1) 106-115; DOI: https://doi.org/10.1124/jpet.113.208538
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of residues S426 and S430 in cannabinoid tolerance
  • DAT ligands on Cocaine-Food Choice in Monkeys
  • MDPV high-responders to evaluate candidate medications
Show more Behavioral Pharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics